Optimize Current Medications Before Adding New Agents
Your patient is on subtherapeutic doses of both medications—increase mirtazapine to 45 mg at bedtime first, as this is the most evidence-based intervention for persistent insomnia in this scenario. 1
Why This Approach
The current regimen uses:
- Doxepin 10 mg: This is within the therapeutic range (3-6 mg for insomnia per guidelines), though some patients may benefit from titration to the higher end
- Mirtazapine 30 mg: This is a mid-range dose, but the FDA-approved maximum is 45 mg daily 1
Mirtazapine has paradoxical dose-dependent effects on sedation. At 15 mg, it's highly sedating due to predominant H1 antihistamine blockade. At 30 mg, sedation may actually decrease as noradrenergic effects increase. At 45 mg, you get both serotonergic/noradrenergic antidepressant effects AND maintained sleep benefits 2. The 30 mg dose may be in a "sweet spot" where sedation is reduced.
Specific Action Plan
Step 1: Titrate Mirtazapine
- Increase mirtazapine from 30 mg to 45 mg at bedtime
- This is the FDA-approved maximum dose 1
- Wait 1-2 weeks to assess response before making further changes 1
- Evidence shows mirtazapine significantly increases total sleep time, sleep efficiency, and slow-wave sleep percentage while reducing wake after sleep onset 3
Step 2: If Still Inadequate After 2 Weeks
Consider these evidence-based options in order of preference per VA/DoD guidelines 4:
Option A: Add Cognitive Behavioral Therapy for Insomnia (CBT-I)
- CBT-I is superior to pharmacotherapy for long-term outcomes 4
- Can be combined with current medications
- Fewer adverse effects than adding more drugs
Option B: Optimize Doxepin
- Current dose (10 mg) exceeds the recommended low-dose range (3-6 mg) for insomnia 4
- Consider reducing to 6 mg rather than increasing—higher doses increase side effects without proven additional benefit for insomnia
- Low-dose doxepin (3-6 mg) improved Insomnia Severity Index scores in older adults with good tolerability 4
Option C: Switch Strategy (if above fails)
- Replace one agent with a dual orexin receptor antagonist (DORA) like suvorexant, lemborexant, or daridorexant 5
- DORAs inhibit wakefulness rather than induce sedation
- No rebound insomnia, withdrawal, or abuse potential 5
- Can be discontinued abruptly without tapering 6
Critical Warnings About Current Regimen
Mirtazapine carries significant risks:
- Somnolence (54% vs 18% placebo) 1
- Weight gain (12% vs 2% placebo) and increased appetite (17% vs 2%) 1
- Rare but serious: agranulocytosis, serotonin syndrome, QT prolongation 1
- Monitor for suicidal ideation, especially in patients <25 years old 1
Common pitfall: Combining two sedating agents (doxepin + mirtazapine) increases risk of:
- Daytime somnolence and cognitive impairment
- Falls (especially in older adults)
- Anticholinergic burden (dry mouth, constipation, confusion)
What NOT to Do
Avoid adding benzodiazepines or trazodone 4:
- Benzodiazepines: Risk of dependency, falls, cognitive impairment, respiratory depression outweighs benefits
- Trazodone: No difference vs placebo in sleep efficiency or discontinuation rates; only improved subjective sleep quality 4
Don't add Z-drugs (zolpidem, eszopiclone) without careful consideration:
- FDA black box warning for serious injuries from complex sleep behaviors (sleep-driving, sleepwalking) 4
- Should only be used at lowest effective dose for shortest duration if prescribed
- Counsel patients on risks
Monitoring Plan
After increasing mirtazapine to 45 mg:
- Assess sleep improvement at 2 weeks (minimum interval for dose changes) 1
- Monitor for increased sedation, weight gain, orthostatic hypotension
- Screen for worsening depression or suicidal thoughts
- Check CBC if fever/infection develops (agranulocytosis risk) 1
If planning to discontinue either medication later: Taper gradually over weeks (10-25% weekly dose reduction) to avoid withdrawal symptoms, especially with mirtazapine after >2 weeks of use 6. Doxepin at low doses may be stopped more abruptly.